Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Boehringer Ingelheim
Colorcon
Johnson and Johnson
Mallinckrodt

Last Updated: August 10, 2022

Details for Patent: 6,811,794


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 6,811,794 protect, and when does it expire?

Patent 6,811,794 protects INTUNIV and is included in one NDA.

Protection for INTUNIV has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 6,811,794
Title: Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
Abstract:A pharmaceutical composition comprising at least one pharmaceutically active agent that is pH dependent, at least one non-pH dependent sustained release agent, and at least one pH dependent agent that increases the dissolution rate of the at least one pharmaceutically active agent at a pH in excess of 5.5. Such compositions have minimized pH-dependent dissolution profiles or pH-independent dissolution profiles.
Inventor(s): Burnside; Beth A. (Bethesda, MD), Chang; Rong-Kun (Rockville, MD), Guo; Xiaodi (New City, NY)
Assignee: Shire Laboratories, Inc. (Rockville, MD)
Application Number:10/027,349
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,811,794
Patent Claim Types:
see list of patent claims
Composition; Compound; Use; Dosage form;

Drugs Protected by US Patent 6,811,794

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Takeda Pharms Usa INTUNIV guanfacine hydrochloride TABLET, EXTENDED RELEASE;ORAL 022037-001 Sep 2, 2009 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Takeda Pharms Usa INTUNIV guanfacine hydrochloride TABLET, EXTENDED RELEASE;ORAL 022037-002 Sep 2, 2009 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Takeda Pharms Usa INTUNIV guanfacine hydrochloride TABLET, EXTENDED RELEASE;ORAL 022037-003 Sep 2, 2009 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
McKinsey
Merck
Medtronic
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.